Role of Glutamate Transport in Alcohol Withdrawal

Osama A. Abulseoud, Christina L. Ruby, Victor M Karpyak

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Glutamate is the major excitatory neurotransmitter in the brain. However, excessive glutamate can lead to neurotoxicity. Evidence suggests that a hyperglutamatergic brain state is the core pathology behind alcohol withdrawal syndrome (AWS). This hyperglutamatergic state results from upregulation of glutamate receptors, dysregulation of glutamate metabolism, and reduction of synaptic glutamate clearance. Numerous genetic factors along this pathway could modulate the vulnerability or severity of AWS. Benzodiazepines, which facilitate inhibitory neurotransmission, are standard therapeutic agents for acute AWS. While effective in reducing withdrawal severity, benzodiazepines carry risks of sedation, respiratory suppression, and dependence, and they do not correct the persistent hyperglutamatergic state associated with relapse. Data show that ceftriaxone, a ?-lactam antibiotic, upregulates excitatory amino acid transporter 2 (EAAT2) and attenuates withdrawal manifestations in preclinical models. These findings underscore the importance of glutamatergic mechanisms in AWS and suggest that glutamate reuptake may represent a novel target for acute withdrawal and relapse prevention.

Original languageEnglish (US)
Title of host publicationFoundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids
PublisherElsevier Inc.
Pages466-477
Number of pages12
Volume1
ISBN (Print)9780128003763, 9780128002131
DOIs
StatePublished - Mar 23 2016

Fingerprint

Glutamic Acid
Alcohols
Benzodiazepines
Excitatory Amino Acid Transporter 2
Up-Regulation
Lactams
Ceftriaxone
Glutamate Receptors
Brain
Secondary Prevention
Synaptic Transmission
Neurotransmitter Agents
Pathology
Anti-Bacterial Agents
Recurrence
Therapeutics

Keywords

  • Alcohol withdrawal
  • Ceftriaxone
  • Excitatory amino acid transporter
  • Glutamate
  • Prefrontal cortex
  • Striatum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Abulseoud, O. A., Ruby, C. L., & Karpyak, V. M. (2016). Role of Glutamate Transport in Alcohol Withdrawal. In Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids (Vol. 1, pp. 466-477). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-800213-1.00043-2

Role of Glutamate Transport in Alcohol Withdrawal. / Abulseoud, Osama A.; Ruby, Christina L.; Karpyak, Victor M.

Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids. Vol. 1 Elsevier Inc., 2016. p. 466-477.

Research output: Chapter in Book/Report/Conference proceedingChapter

Abulseoud, OA, Ruby, CL & Karpyak, VM 2016, Role of Glutamate Transport in Alcohol Withdrawal. in Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids. vol. 1, Elsevier Inc., pp. 466-477. https://doi.org/10.1016/B978-0-12-800213-1.00043-2
Abulseoud OA, Ruby CL, Karpyak VM. Role of Glutamate Transport in Alcohol Withdrawal. In Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids. Vol. 1. Elsevier Inc. 2016. p. 466-477 https://doi.org/10.1016/B978-0-12-800213-1.00043-2
Abulseoud, Osama A. ; Ruby, Christina L. ; Karpyak, Victor M. / Role of Glutamate Transport in Alcohol Withdrawal. Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids. Vol. 1 Elsevier Inc., 2016. pp. 466-477
@inbook{02de4c1432a74a9f84206bf1659b6610,
title = "Role of Glutamate Transport in Alcohol Withdrawal",
abstract = "Glutamate is the major excitatory neurotransmitter in the brain. However, excessive glutamate can lead to neurotoxicity. Evidence suggests that a hyperglutamatergic brain state is the core pathology behind alcohol withdrawal syndrome (AWS). This hyperglutamatergic state results from upregulation of glutamate receptors, dysregulation of glutamate metabolism, and reduction of synaptic glutamate clearance. Numerous genetic factors along this pathway could modulate the vulnerability or severity of AWS. Benzodiazepines, which facilitate inhibitory neurotransmission, are standard therapeutic agents for acute AWS. While effective in reducing withdrawal severity, benzodiazepines carry risks of sedation, respiratory suppression, and dependence, and they do not correct the persistent hyperglutamatergic state associated with relapse. Data show that ceftriaxone, a ?-lactam antibiotic, upregulates excitatory amino acid transporter 2 (EAAT2) and attenuates withdrawal manifestations in preclinical models. These findings underscore the importance of glutamatergic mechanisms in AWS and suggest that glutamate reuptake may represent a novel target for acute withdrawal and relapse prevention.",
keywords = "Alcohol withdrawal, Ceftriaxone, Excitatory amino acid transporter, Glutamate, Prefrontal cortex, Striatum",
author = "Abulseoud, {Osama A.} and Ruby, {Christina L.} and Karpyak, {Victor M}",
year = "2016",
month = "3",
day = "23",
doi = "10.1016/B978-0-12-800213-1.00043-2",
language = "English (US)",
isbn = "9780128003763",
volume = "1",
pages = "466--477",
booktitle = "Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Role of Glutamate Transport in Alcohol Withdrawal

AU - Abulseoud, Osama A.

AU - Ruby, Christina L.

AU - Karpyak, Victor M

PY - 2016/3/23

Y1 - 2016/3/23

N2 - Glutamate is the major excitatory neurotransmitter in the brain. However, excessive glutamate can lead to neurotoxicity. Evidence suggests that a hyperglutamatergic brain state is the core pathology behind alcohol withdrawal syndrome (AWS). This hyperglutamatergic state results from upregulation of glutamate receptors, dysregulation of glutamate metabolism, and reduction of synaptic glutamate clearance. Numerous genetic factors along this pathway could modulate the vulnerability or severity of AWS. Benzodiazepines, which facilitate inhibitory neurotransmission, are standard therapeutic agents for acute AWS. While effective in reducing withdrawal severity, benzodiazepines carry risks of sedation, respiratory suppression, and dependence, and they do not correct the persistent hyperglutamatergic state associated with relapse. Data show that ceftriaxone, a ?-lactam antibiotic, upregulates excitatory amino acid transporter 2 (EAAT2) and attenuates withdrawal manifestations in preclinical models. These findings underscore the importance of glutamatergic mechanisms in AWS and suggest that glutamate reuptake may represent a novel target for acute withdrawal and relapse prevention.

AB - Glutamate is the major excitatory neurotransmitter in the brain. However, excessive glutamate can lead to neurotoxicity. Evidence suggests that a hyperglutamatergic brain state is the core pathology behind alcohol withdrawal syndrome (AWS). This hyperglutamatergic state results from upregulation of glutamate receptors, dysregulation of glutamate metabolism, and reduction of synaptic glutamate clearance. Numerous genetic factors along this pathway could modulate the vulnerability or severity of AWS. Benzodiazepines, which facilitate inhibitory neurotransmission, are standard therapeutic agents for acute AWS. While effective in reducing withdrawal severity, benzodiazepines carry risks of sedation, respiratory suppression, and dependence, and they do not correct the persistent hyperglutamatergic state associated with relapse. Data show that ceftriaxone, a ?-lactam antibiotic, upregulates excitatory amino acid transporter 2 (EAAT2) and attenuates withdrawal manifestations in preclinical models. These findings underscore the importance of glutamatergic mechanisms in AWS and suggest that glutamate reuptake may represent a novel target for acute withdrawal and relapse prevention.

KW - Alcohol withdrawal

KW - Ceftriaxone

KW - Excitatory amino acid transporter

KW - Glutamate

KW - Prefrontal cortex

KW - Striatum

UR - http://www.scopus.com/inward/record.url?scp=84969700023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969700023&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-800213-1.00043-2

DO - 10.1016/B978-0-12-800213-1.00043-2

M3 - Chapter

SN - 9780128003763

SN - 9780128002131

VL - 1

SP - 466

EP - 477

BT - Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids

PB - Elsevier Inc.

ER -